Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant
Kevin K. Ariën, Leo Heyndríckx, Johan Míchiels, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium
Irith De Baetselier, Christophe Van Dijck, Chris Kenyon, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2288-2292
Open Access | Times Cited: 237
Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas
Paul Christensen, Randall J. Olsen, Sheng Long, et al.
American Journal Of Pathology (2022) Vol. 192, Iss. 4, pp. 642-652
Open Access | Times Cited: 201
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
Kirsten E. Lyke, Robert L. Atmar, Clara Domínguez Islas, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 7, pp. 100679-100679
Open Access | Times Cited: 144
Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
Laurent Rénia, Yun Shan Goh, Angéline Rouers, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Recent insights into SARS‐CoV‐2 omicron variant
Severino Jefferson Ribeiro da Silva, Alain Kohl, Lindomar Pena, et al.
Reviews in Medical Virology (2022) Vol. 33, Iss. 1
Open Access | Times Cited: 43
Neutralizing antibodies to SARS‐CoV‐2 variants of concern including Delta and Omicron in subjects receiving mRNA‐1273, BNT162b2, and Ad26.COV2.S vaccines
Fei Zhang, Wen Meng, Luping Chen, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 12, pp. 5678-5690
Open Access | Times Cited: 32
Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection
Endeshaw Chekol Abebe, Markeshaw Tiruneh G Medhin, Awgichew Behaile T Mariam, et al.
Infection and Drug Resistance (2022) Vol. Volume 15, pp. 1871-1887
Open Access | Times Cited: 30
Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial
Suad Hannawi, Linda Saf Eldin, Alaa Abuquta, et al.
EBioMedicine (2022) Vol. 87, pp. 104386-104386
Open Access | Times Cited: 27
Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review
Yuxuan Du, Long Chen, Yuan Shi
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 5
Open Access | Times Cited: 25
Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron Variant
Kirsten E. Lyke, Robert L. Atmar, Clara Domínguez Islas, et al.
SSRN Electronic Journal (2022)
Closed Access | Times Cited: 25
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial
Shabir A. Madhi, Gaurav Kwatra, Simone I. Richardson, et al.
The Lancet Infectious Diseases (2022) Vol. 23, Iss. 3, pp. 295-306
Open Access | Times Cited: 21
Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients
Lorenzo Canti, Kevin K. Ariën, Isabelle Desombere, et al.
Cancer Cell (2022) Vol. 40, Iss. 4, pp. 335-337
Open Access | Times Cited: 20
COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
Dorota Zarębska‐Michaluk, Chenlin Hu, Michał Brzdęk, et al.
Vaccines (2022) Vol. 10, Iss. 8, pp. 1223-1223
Open Access | Times Cited: 20
Progress with COVID vaccine development and implementation
Richard W. Titball, David I. Bernstein, Nicolas V. J. Fanget, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 3
A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity
Peng Du, Ning Li, Xinxin Xiong, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 9, pp. 4287-4293
Closed Access | Times Cited: 16
Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant
Ioannis Sitaras, Henning Jacobsen, Melissa M. Higdon, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 16
Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2
Molly R. Braun, C Martínez, Emery G. Dora, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Inferior cellular and humoral immunity against Omicron and Delta variants of concern compared with SARS-CoV-2 wild type in hemodialysis patients immunized with 4 SARS-CoV-2 vaccine doses
Moritz Anft, Arturo Blázquez-Navarro, Michael Frahnert, et al.
Kidney International (2022) Vol. 102, Iss. 1, pp. 207-208
Open Access | Times Cited: 14
Inactivation of SARS-CoV-2 and Other Enveloped and Non-Enveloped Viruses with Non-Thermal Plasma for Hospital Disinfection
Maxime Sahun, Angela Privat‐Maldonado, Abraham Lin, et al.
ACS Sustainable Chemistry & Engineering (2023) Vol. 11, Iss. 13, pp. 5206-5215
Open Access | Times Cited: 8
SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?
Rohan Ameratunga, Euphemia Leung, See‐Tarn Woon, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 9, pp. 2267-2273
Open Access | Times Cited: 13
Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV
Frédérique Chammartin, Katharina Kusejko, Chloé Pasin, et al.
AIDS (2022) Vol. 36, Iss. 10, pp. 1465-1468
Open Access | Times Cited: 13
Two Years of Genomic Surveillance in Belgium during the SARS-CoV-2 Pandemic to Attain Country-Wide Coverage and Monitor the Introduction and Spread of Emerging Variants
Lize Cuypers, Simon Dellicour, Samuel L. Hong, et al.
Viruses (2022) Vol. 14, Iss. 10, pp. 2301-2301
Open Access | Times Cited: 13
SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations
Andrew P. Hederman, Harini Natarajan, Leo Heyndríckx, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients
Alexandra Tauzin, Guillaume Beaudoin-Bussières, Shang Yu Gong, et al.
iScience (2022) Vol. 25, Iss. 9, pp. 104990-104990
Open Access | Times Cited: 11
Younger Children Develop Higher Effector Antibody Responses to SARS-CoV-2 Infection
Lisa Tomasi, Anaïs Thiriard, Leo Heyndríckx, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 11
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top